title: 2-weekly versus 3-weekly docetaxel for prostate cancer.
authors.affiliation: Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA. dnanus@med.cornell.edu
authors.forename: David M
authors.initials: DM
authors.lastname: Nanus
authors.forename: Scott T
authors.initials: ST
authors.lastname: Tagawa
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel